Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AKT1 | P31749 | 7/20 | 0.65 |
| ▸ | PDPK1 | O15530 | 2/20 | 0.65 |
| ▸ | PHLPP1 | O60346 | 2/20 | 0.65 |
| ▸ | ILK | Q13418 | 2/20 | 0.65 |
| ▸ | ALOX5 | P09917 | 10/20 | 0.64 |
| ▸ | PTGES | O14684 | 1/20 | 0.56 |
| ▸ | NR1I2 | O75469 | 2/20 | 0.45 |
| ▸ | PPARG | P37231 | 1/20 | 0.45 |
| ▸ | PPARA | Q07869 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL407517 | 1.00 | AKT1 (0.65) | AKT1PDPK1PHLPP1ILKALOX5 | |
| SCHEMBL5441388 | 1.00 | AKT1 (0.65) | AKT1PDPK1PHLPP1ILKALOX5 | |
| SCHEMBL29393858 | 1.00 | AKT1 (0.65) | AKT1PDPK1PHLPP1ILKALOX5 | |
| SCHEMBL19659847 | 0.90 | AKT1 (0.65) | AKT1PDPK1PHLPP1ILKALOX5 | |
| SCHEMBL4193356 | 0.87 | AKT1 (0.60) | AKT1PDPK1PHLPP1ILKALOX5 | |
| SCHEMBL5772966 | 0.86 | AKT1 (0.61) | AKT1PDPK1PHLPP1ILKALOX5 | |
| SCHEMBL4780480 | 0.85 | ALOX5 (0.51) | AKT1PDPK1PHLPP1ILKALOX5 | |
| SCHEMBL14580950 | 0.84 | AKT1 (0.70) | AKT1PDPK1PHLPP1ILKALOX5 | |
| SCHEMBL18212526 | 0.84 | AKT1 (0.70) | AKT1PDPK1PHLPP1ILKALOX5 | |
| SCHEMBL5771546 | 0.84 | AKT1 (0.70) | AKT1PDPK1PHLPP1ILKALOX5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 28 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1270004-B1 | USE OF GAMMA-TOCOTRIENOL AS DIURETIC | EISAI R&D MAN CO LTD (JP) | 2010-06-09 | — | — | EP | disclosed |
| US-20070037878-A1 | Use of gamma-tocopherol and its oxidative metabolite LLU-alpha in the treatment of disease | WECHTER WILLIAM J | 2007-02-15 | — | — | US | disclosed |
| US-20070037879-A1 | Use of gamma-tocopherol and its oxidative metabolite LLU-alpha in the treatment of disease | WECHTER WILLIAM J | 2007-02-15 | — | — | US | disclosed |
| US-20070037878-A1 | Use of gamma-tocopherol and its oxidative metabolite LLU-alpha in the treatment of disease | WECHTER WILLIAM J | 2007-02-15 | — | — | US | disclosed |
| US-20070037879-A1 | Use of gamma-tocopherol and its oxidative metabolite LLU-alpha in the treatment of disease | WECHTER WILLIAM J | 2007-02-15 | — | — | US | disclosed |
| US-20070037879-A1 | Use of gamma-tocopherol and its oxidative metabolite LLU-alpha in the treatment of disease | WECHTER WILLIAM J | 2007-02-15 | — | — | US | disclosed |
| US-20070037878-A1 | Use of gamma-tocopherol and its oxidative metabolite LLU-alpha in the treatment of disease | WECHTER WILLIAM J | 2007-02-15 | — | — | US | disclosed |
| US-20060223881-A1 | Use of gamma- tocopherol and its oxidative metabolite LLU-alpha in the treatment of disease | WECHTER WILLIAM J | 2006-10-05 | — | — | US | disclosed |
| US-6908943-B2 | Use of γ-tocopherol and its oxidative metabolite LLU-α in the treatment of disease | LOMA LINDA UNIVERSITY MEDICAL CENTER (US) | 2005-06-21 | — | — | US | disclosed |
| US-6864280-B2 | Hypotensive agents; cardiovascular disorders | EISAI CO., LTD. (JP) | 2005-03-08 | — | — | US | disclosed |
| US-6410589-B2 | Use of γ-tocopherol and its oxidative metabolite LLU-α in the treatment of disease | LOMA LINDA UNIVERSITY MEDICAL CENTER | 2002-06-25 | — | — | US | disclosed |
| US-20010031782-A1 | Use of gamma-tocopherol and its oxidative metabolite LLU-alpha in the treatment of disease | WECHTER WILLIAM J (US) | 2001-10-18 | — | — | US | disclosed |
| EP-1140065-A1 | USE OF GAMMA-TOCOPHEROL AND ITS OXIDATIVE METABOLITE LLU-ALPHA IN THE TREATMENT OF DISEASE | LOMA LINDA UNIVERSITY MEDICAL CENTER (US) | 2001-10-10 | — | — | EP | disclosed |
| US-6242479-B1 | ADMINISTERING ORALLY OR PARENTALLY TO PREVENT CARDIOVASCULAR, NERVOUS SYSTEM, OR BRAIN DISORDERS; ANTIOXIDANTS, ANTICOAGULANTS, HYPOTENSIVE AGENTS; ATHEROSCLEROSIS | LOMA LINDA UNIVERSITY MEDICAL CENTER | 2001-06-05 | — | — | US | disclosed |
| US-6150402-A | Natriuretic compounds | LOMA LINDA UNIVERSITY MEDICAL CENTER (US) | 2000-11-21 | — | — | US | disclosed |
| US-6083982-A | STIMULATING SODIUM EXCRETION IN THE URINE OF A MAMMAL COMPRISING ADMINISTERING TO THE MAMMAL A ALKOXYALKYL OR HYDROXY ALKYL SUBSTITUTED PHENOLIC COMPOUND | LOMA LINDA UNIVERSITY MEDICAL (US) | 2000-07-04 | — | — | US | disclosed |
| WO-2000035444-A1 | USE OF η-TOCOPHEROL AND ITS OXIDATIVE METABOLITE LLU-α IN THE TREATMENT OF DISEASE | LOMA LINDA UNIVERSITY MEDICAL CENTER (US) | 2000-06-22 | — | — | WO | disclosed |
| US-6048891-A | ADMINISTERING MIXTURES WITH 6-HYDROXY-2,7,8-TRIMETHYL-CHROMAN-2-PROPANOIC ACID FOR TREATMENT OF CARDIOVASCULAR AND KIDNEY DISORDERS | LOMA LINDA UNIVERSITY MEDICAL CENTER (US) | 2000-04-11 | — | — | US | disclosed |
| EP-0792270-A1 | NATRIURETIC CYCLIC COMPOUNDS | LOMA LINDA UNIVERSITY MEDICAL CENTER (US) | 1997-09-03 | — | — | EP | disclosed |
| WO-1996005191-A1 | NATRIURETIC CYCLIC COMPOUNDS | LOMA LINDA UNIVERSITY MEDICAL CENTER (US) | 1996-02-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070037879-A1 | Use of gamma-tocopherol and its oxidative metabolite LLU-alpha in the treatment of disease | TTPA, LTA, GSTM1 | AKT1 3368/4885PDPK1 4164/4885PHLPP1 3614/4885 |
| US-20070037878-A1 | Use of gamma-tocopherol and its oxidative metabolite LLU-alpha in the treatment of disease | TTPA, LTA, GSTM1 | AKT1 3368/4885PDPK1 4164/4885PHLPP1 3614/4885 |
| US-20060223881-A1 | Use of gamma- tocopherol and its oxidative metabolite LLU-alpha in the treatment of disease | TTPA, LTA, GSTM1 | AKT1 3368/4885PDPK1 4164/4885PHLPP1 3614/4885 |
| US-20010031782-A1 | Use of gamma-tocopherol and its oxidative metabolite LLU-alpha in the treatment of disease | TTPA, LTA, LPO | AKT1 3599/4885PDPK1 4172/4885PHLPP1 3792/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.